Shc is an adapter protein that has been implicated in Ras activation following the stimulation of a number of different receptors, including those of growth factors [insulin, epidermal growth factor (EGF), nerve growth factor, and platelet-derived growth factor (PDGF)] (1-6), cytokines (interleukins 2, 3, and 5), erythropoietin, and granulocyte/ macrophage colony-stimulating factor (7) (8) (9) , and antigens (e.g. T-cell and B-cell receptors) (10, 11) . Shc has been shown to bind to tyrosine-phosphorylated receptors, and receptor stimulation leads to tyrosine phosphorylation of Shc. Upon phosphorylation, Shc interacts with another adapter protein, Grb2, which binds to the Ras GTP/GDP exchange factor mSOS. The simultaneous interaction of Shc with the activated receptor and Grb2 may help to shuttle the exchange factor mSOS. The simultaneous interaction of Shc with the activated receptor and Grb2 may help to shuttle the exchange factor mSOS to the membrane, which leads to Ras activation.
Shc is ubiquitously expressed and exists in three isoforms of 66, 52, and 48 kDa (2) . The protein is composed of an N-terminal domain that has been recently shown to interact with proteins containing phosphorylated tyrosines (12, 13) , a (glycine/proline)-rich collagen-homology domain that contains the phosphorylated binding site (Tyr-317) for the SH2 domain of Grb2, and a C-terminal Src-homology 2 (SH2) domain. SH2 domains are found in a number of intracellular signaling molecules and bind to specific phosphotyrosine-containing sequences (14) . The SH2 domain of Shc has been shown to interact with the tyrosine-phosphorylated receptors of EGF (2) and PDGF (4) . In addition, the Shc SH2 domain interacts with the tyrosine-phosphorylated ߞ chain of the T-cell receptor, providing one of the mechanisms of T-cell-mediated Ras activation (10) .
Three-dimensional (3D) structures of SH2 domains have been determined by NMR and x-ray crystallography when bound to peptides containing phosphorylated tyrosines (15) (16) (17) (18) . However, no structure of the Shc SH2 domain either alone or when complexed to a phosphopeptide has been reported.
Abbreviation : COSY, correlated spectroscopy; TOCSY, total correlated spectroscopy; NOE, nuclear Overhauser effect; NOESY, NOE spectroscopy; 2D, two-dimensional; 3D, three-dimensional; rmsd, rms deviation; PLC-ߛ1,phospholipase C-ߛ1. † Present address: Institute of Molecular Biophysics, Florida State University, Tallahassee, FL 32306-3915. § To whom reprint requests should be addressed.
||
The nomenclature used in this paper to describe the secondary structural elements of SH2 domains is that of Harrison and coworkers (15) .
Although the SH2 domain of Shc is homologous to other SH2 domains, there are some distinct differences: (i) the ߚD6 residue, || which is part of the phosphotyrosine-binding pocket, is a leucine in Shc rather than a lysine or arginine as in other SH2 domains; (ii) the ߚD5 residue, which has been implicated in regulating the binding specificity of SH2 domains (19) , is a leucine in Shc, a residue not found at this position in any of the known SH2 domains; (iii) the lengths of the loops between regular elements of secondary structure, which could reflect differences in the tertiary structure and binding specificities, are different in Shc compared to other SH2 domains. To determine whether these differences in primary structure result in alterations in the tertiary structure of this SH2 domain and to gain a better understanding of the Shc's binding specificity, we sought to determine the solution structures of Shc SH2 /peptide complexes. Here we describe a high-resolution NMR structure of the Shc SH2 domain complexed with a phosphotyrosine-containing peptide corresponding to a portion of the ߞ chain of the Tcell receptor.
MATERIALS AND METHODS
Preparation of NMR Samples. The Shc SH2 domain, corresponding to residues 370-473 of the full Shc protein (2) , was subcloned into the pET20b plasmid (Novagen) and expressed in Escherichia coli BL21(DE3) cells. The protein contained an additional Leu-Glu-(His) 6 sequence at the C terminus to aid in protein purification. The SH2 domain of Shc was purified by affinity chromatography on a nickel-IDA column (Invitrogen), followed by HPLC ion-exchange chromatography in 20 mM sodium phosphate buffer (pH 7.8). Uniformly (24), HNCO (25) , HN(CA)CO (25) , HACACO (26) , (H)C(CO)NH-TOCSY (27) , HCCH-TOCSY (28) , and CCH-COSY (29) experiments (where COSY is correlated spectroscopy, TOCSY is total correlated spectroscopy, and NOESY is nuclear Overhauser effect spectroscopy). The Val and Leu methyl groups were stereospecifically assigned using the approach described by W‫ݑ‬ሷ thrich and coworkers (30) H HSQC spectra. Structure Calculations. Structure calculations were performed using the X-PLOR (33) program following the distance geometry/simulated annealing protocol described in the X-PLOR manual (34) . A total of 1995 intramolecular and 77 intermolecular NOE-derived distance restraints were used in the structure calculations. On the basis of the integrated NOE cross peak volumes, these NOE restraints were grouped into three ranges (1.8-3.0 Å, 1.8-4.0 Å, and 1.8-5.0 Å), corresponding to strong, medium, and weak NOEs, respectively. Upper limits for distances involving methyl protons, nonstereospecifically assigned methylene protons, and aromatic ring protons were corrected for center averaging (35) . In addition to the NOE-derived restraints, 36 ߶ angle restraints derived from 3 J ୌ ొ ୌ ಉ coupling constants measured from HMQC-J spectra were included using bounds of -120 ± 40°for those angles with 3 J ୌ ొ ୌ ಉ coupling constants > 9.0 Hz and -60 ± 40°for 3 J ୌ ొ ୌ ಉ coupling constants <5.5 Hz. Restraints for the latter were applied only in ߙ-helical regions of the protein that were defined from 13 
‫ܥ‬
ఈ chemical shifts and characteristic NOEs. A total of 35 hydrogen bond restraints were also included in the structure calculations with bounds of 1.8-2.5 Å (H→0) and 2.5-3.3 Å (N→0). The amides involved in hydrogen bonds were identified based on the slowly exchanging amide protons observed in 2D 
RESULTS AND DISCUSSION
Peptide Binding Affinity. To determine which phosphopeptide to use in our NMR studies, the binding affinities of the Shc SH2 domain were measured for two phosphopeptides corresponding to portions of the third tyrosine-based activation motif of the ߞ chain of the T-cell receptor. Since the N-terminal peptide of the third tyrosine-based activation motif (GHDGLpYQGLSTATK) was found to bind more tightly (50 ‫ܯߤ‬ ) to the Shc SH2 domain compared to ATKDTpYDALHMQA (650 ‫ܯߤ‬ ), the N-terminal peptide was chosen for the NMR studies.
NMR Assignments and Structure Determination. The C-filtered (Fl), 13 C-edited (F3) 3D NOESY spectrum. The 3D structure of the Shc SH2 domain/peptide complex was determined using a distance geometry/simulated annealing protocol (33, 34) from a total of 2143 NMR-derived restraints. All of the structures satisfy the experimental distance restraints with no violations >0.1 Å and show good covalent geometry and nonbonded contacts ( Table 1 ). The backbone is well-defined by the NMR data ( Fig. 1) except for the first residue at the N terminus and the last eight residues (LEHHHHHH) at the C terminus, which contains the histidine tag ( Table 1 ). The portion of the phosphopeptide that contacts the protein (residues 6-9) is constrained by the NMR data. However, the remaining peptide residues (1-5, 10-14) are not well-defined by the limited number of NMR-derived restraints involving these residues. The atomic rmsd about the mean coordinate positions for the protein residues 2-104 and peptide residues 6-9 of the complex is 0.39 ± 0.05 Å for the backbone atoms and 0.82 ± 0.04 Å for all heavy atoms.
Structure of the Shc SH2 Domain/Peptide Complex. Fig. 2A shows a schematic ribbon diagram of the NMR-derived structure of the Shc SH2/peptide complex. The structure consists of a three-stranded antiparallel ߚ-sheet composed of strands ߚB, ߚC, and ߚD that is flanked on each side by two ߙ-helices. The central ߚ-sheet is extended by two short parallel strands (ߚA and ߚG) located on the opposite side of the peptide-binding site. The protein also contains a second, smaller ߚ-sheet-like structure composed of strands ߚD', ߚE, and ߚF. As shown in Fig. 2 , the structure of the central ߚ-sheet and flanking helices of the Shc SH2 domain is similar to that of other SH2 domains whose structures have been previously determined (15) (16) (17) (18) . However, the position of strands ߚD' and ߚE is different in the Shc SH2 domain due to a kink between ߚD and ߚD' (Fig. 2A) . Furthermore, unlike in other SH2 domains, the ߚD'1 residue of Shc does not form hydrogen bonds to the ߚE strand. Instead, the NMR data suggest that the ߚD'2 residue hydrogen bonds to the ߚE strand. Another distinguishing feature of the Shc SH2 domain is the relatively long length of the BG loop that contacts the peptide. Although the Syp SH2 domain has a BG loop of similar size, it is more hydrophilic and is located in a different position compared to Shc (Fig. 2) .
As in other SH2 domains, the phosphopeptide adopts an extended conformation and binds to the Shc SH2 domain almost perpendicular to the ߚD strand of the central sheet ( Fig. 2A) . However, the location of the phosphopeptide relative to the protein is different in Shc compared to other SH2 domains (Fig. 3) . In Shc, the phosphopeptide binds between the DE and BG loops ( Fig. 2A) , whereas, in Lck, PLC-ߛl, and Syp, the phosphopeptide is located between the EF and BG loops (Fig. 2 B-D) . The relatively long BG loop in Shc contacts the peptide and together with the DE loop forms a large cleft (Fig. 2A) .
The phosphotyrosine-binding pocket in the Shc SH2 domain is formed by Arg ߙA2, Arg ߚB5, Val ߚC3, His ߚD4, and Leu ߚD6 (Fig. 4) . The plane of the imidazole ring of the His ߚD4 is almost perpendicular to the plane of the aromatic ring of P-Tyr, forming aromatic-aromatic interactions, whereas the methyl groups of Val ߚC3 and Leu ߚD5 form hydrophobic interactions with the aromatic ring of the P-Tyr residue. Arg ߚB6 is located at the bottom of the P-Tyr-binding pocket. This residue is strictly conserved in the known SH2 domains and is part of the FLVR signature sequence of all SH2 domains (14) . Since the NMR signals corresponding to the exchangeable Nߟ) protons of Arg ߚB5 are observable in aqueous solution, these protons must be sequestered from solvent and are probably directly interacting with the negatively charged phosphate. Arg ߙA2 is also in close proximity to the P-Tyr residue of the peptide. However, unlike Arg ߚB5, the N-ߟ protons were not observed and the linewidth of the Nߝ proton signal of Arg ߙA2 was quite broad, suggesting that this arginine residue may be more flexible than the Arg ߚB5 in the P-Tyr-binding pocket. In general, it appears that Arg ߙA2 residue is less critical than Arg ߚB5 for P-Tyr binding in SH2 domains. Mutation of Arg ߙA2 to Ala in the GTPaseactivating protein SH2 domain only reduced the affinity but did not abolish P-Tyr binding (40) . In addition, the Syp SH2 domain has a Gly residue at this position.
Compared to Syp, PLC-ߛ1, or Src-like SH2 domains in which a highly conserved positively charged residue is located at the ߚD6 position (a lysine in Src-like and Syp SH2 domains and an arginine in PLC-ߛ1 SH2 domain), the Shc SH2 domain contains a leucine at this position (Fig. 5) . In the crystal structure of the Src SH2 domain/phosphopeptide complex, the Lys ߚD6 residue contributes to P-Tyr binding through hydrophobic and electrostatic interactions with P-Tyr. In addition, this Lys residue is hydrogen bonded to Thr BC3 in the phosphate-binding BC loop, resulting in the formation of an extensive hydrogen bonding network involving Glu BC1, Thr BC2, and the phosphate of the P-Tyr. The corresponding ߚD6 residue in Lck, Syp, and PLC-ߛl SH2 domains appears to have a similar function to that of the Src SH2 domain. In contrast, the Shc SH2 domain with a leucine ߚD6 residue lacks this network of hydrogen bonds involving the BC loop. Despite the loss of hydrogen bonds, however, the phosphate binding sites in Shc and the other SH2 domains are similar with the exception of a slight positional difference of the BC loop (Fig. 4) . This phosphate-binding interaction loss in Shc may be at least partially compensated by additional hydrophobic interactions between the P-Tyr residue and Leu ߚD6 and Val ߚC3 residues of the Shc SH2 domain.
The (pY + 1) Gln residue of the phosphopeptide is in close proximity to the side chains of Leu ߚD5 and Ala BG7. In other SH2 domains, the ߚD5 residue has been proposed to have a major influence on the binding specificity of phosphorylated peptides for SH2 domains. The hydrophobic Leu residue at the ߚD5 position in Shc that interacts with the aliphatic side chain of Gln is consistent with the preference for hydrophobic residues (Ile, Tyr, and Leu) at (pY + 1). Analogous to the interactions with Gln of the phosphorylated peptide, the Leu ߚD5 residue could interact with the aliphatic portion of a glutamic acid that is also preferred at this site. In this regard, the C-terminal SH2 domain of Shc more closely resembles the SH2 domains of PLC-ߛ1 and Syp that have either a Cys or Ile at the ߚD5 position rather than the Src-like SH2 domains that have a ߚD5 Tyr or Phe.
The side chain of the (pY + 2) Gly residue sits on the top of the binding site. Only one NOE was observed between the ‫ܪ‬ ఈ protons of the (pY + 2) Gly residue and the protein. The side chain of an L-amino acid, if present, would poke out toward solvent, which is consistent with the lack of selectivity at this position for binding to the Shc SH2 domain.
The Leu side chain at the (pY+3) position interacts with the protein in a hydrophobic pocket located on the other side of the central ߚ-sheet ( Fig. 2A and 4) . The binding pocket is formed by hydrophobic residues from strands ߚD and ߚE, the BG loop, and helix ߙB at the bottom of the groove. Extensive contacts were observed between Leu at (pY + 3) and the backbone of Arg ߚE3 and the side chains of residues Leu ߚD5, Leu ߚD7, Val ߚE2, Thr ߚE4, Phe ߚF3, Leu ߙB5, Ile BG4, Ser BG6, and Leu BG11 in the binding pocket of Shc (Fig.  4) . The amino acid residues that make up this binding pocket in Shc are different from those of Src, Lck, Syp, and PLC-ߛl. The (pY + 3) Leu in Shc is much closer to the fo strand and N-terminal end of the pE strand, making extensive contacts with ߚD7, ߚE2, and ߚE3 residues. In contrast, the corresponding residues in other SH2 domains were not part of the (pY + 3) binding pocket. On the other hand, the EF1 and EF3 residues that interact extensively with the (pY + 3) residue of the phosphopeptide in the other SH2 domains are far away from the peptide in Shc.
The other residues of the bound phosphopeptide are ill-defined by the NMR data. No intermolecular NOEs were observed involving these peptide residues except for three NOEs between the Ala residue at the (pY + 4) position and Ile BG5 and Ser BG6. Thus, in contrast to the Syp and PLC-ߛ1 SH2 domain/peptide complexes, peptide residues beyond the (pY + 4) position do not contact the protein.
In summary, we have determined a high-resolution NMR structure of the C-terminal SH2 domain of Shc complexed to a tyrosine-phosphorylated peptide from the ߞ chain of the T-cell receptor. Although the overall architecture of the protein is similar to other SH2 domains, distinct structural differences were observed in the smaller ߚ-sheet, BG loop, relative position of the bound phosphopeptide, and (pY + 3) binding site. In addition, the Shc SH2 domain contains a Leu residue at the ߚD6 position that cannot form an extensive hydrogen-bonding network involving the BC loop as found in some of the other SH2 domains. This may help explain the relatively low binding affinity for phosphotyrosine-containing peptides displayed by the SH2 domain of Shc and other proteins containing a hydrophobic residue at this position (proteins such as GAP, p85 PI-3 kinase, and Zap70). To compensate for the low binding affinity, some proteins contain more than one SH2 domain, which can markedly increase the binding affinity and specificity of these proteins. Although Shc only contains one SH2 domain, the N terminus of Shc has recently been shown to bind to proteins containing phosphorylated tyrosines. Thus, the N-terminal phosphotyrosinebinding domain and C-terminal SH2 domain of Shc may bind to multiply phosphorylated proteins, increasing the affinity and selectivity of Shc for binding to its target proteins.
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